{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:09Z","timestamp":1791920889344,"version":"4.3.4"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"am","delay-in-days":640,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1RO1-MH-116695"],"award-info":[{"award-number":["1RO1-MH-116695"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["113,115,116"],"award-info":[{"award-number":["113,115,116"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["117,118"],"award-info":[{"award-number":["117,118"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["120,121"],"award-info":[{"award-number":["120,121"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["122,123"],"award-info":[{"award-number":["122,123"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Center for AIDS Research, Emory University","doi-asserted-by":"publisher","award":["P30-AI050409"],"award-info":[{"award-number":["P30-AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejmech.2022.114554","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T20:40:54Z","timestamp":1655757654000},"page":"114554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["HIV nucleoside reverse transcriptase inhibitors"],"prefix":"10.1016","volume":"240","author":[{"given":"Franck","family":"Amblard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmeshkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Michailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kasthuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Biteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahira","family":"Tber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ehteshami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114554_bib1","series-title":"The Global HIV\/AIDS Epidemic","year":"2021"},{"key":"10.1016\/j.ejmech.2022.114554_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J. Int. AIDS Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib3","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from Lab to Clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"26","key":"10.1016\/j.ejmech.2022.114554_bib5","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2174\/092986710792065045","article-title":"HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development","volume":"17","author":"Tramontano","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/17584310.3.1.39","article-title":"HIV ribonuclease H: continuing the search for small molecule antagonists","volume":"3","author":"Wendeler","year":"2009","journal-title":"HIV Ther."},{"issue":"2A","key":"10.1016\/j.ejmech.2022.114554_bib7","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib8","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ejmech.2022.114554_bib9","series-title":"Adv. Pharmacol.","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","article-title":"Chapter Nine - the nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS)","author":"De Clercq","year":"2013"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib11","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem. Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/PL00000626","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"57","author":"Sluis-Cremer","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","article-title":"Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine","volume":"85","author":"Cihlar","year":"2010","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2008.07.008","article-title":"Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues","volume":"4","author":"Lisco","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib15","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.05986-11","article-title":"Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin","volume":"56","author":"Vanpouille","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/cid\/civ172","article-title":"Valacyclovir decreases plasma HIV-1 RNA in HSV-2 seronegative individuals: a randomized placebo-controlled crossover trial","volume":"60","author":"Vanpouille","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2022.114554_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors","volume":"134","author":"Sluis-Cremer","year":"2008","journal-title":"Virus Res."},{"issue":"21","key":"10.1016\/j.ejmech.2022.114554_bib18","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1021\/acs.jmedchem.9b01289","article-title":"Structural basis of HIV-1 inhibition by nucleotide-competing reverse transcriptase inhibitor INDOPY-1","volume":"62","author":"Ruiz","year":"2019","journal-title":"J. Med. Chem."},{"issue":"44","key":"10.1016\/j.ejmech.2022.114554_bib19","doi-asserted-by":"crossref","first-page":"29904","DOI":"10.1074\/jbc.M804882200","article-title":"Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against \"nucleotide-competing reverse transcriptase inhibitors","volume":"283","author":"Ehteshami","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2022.114554_bib20","doi-asserted-by":"crossref","first-page":"17336","DOI":"10.1074\/jbc.M112.433441","article-title":"Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer","volume":"288","author":"Ehteshami","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2022.114554_bib21","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1128\/JVI.00889-06","article-title":"Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action","volume":"80","author":"Jochmans","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib23","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3018(21)00021-7","article-title":"Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial","volume":"8","author":"Molina","year":"2021","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.ejmech.2022.114554_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(02)02054-0","article-title":"Targeting HIV: antiretroviral therapy and development of drug resistance","volume":"23","author":"Men\u00e9ndez-Arias","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/acs.accounts.9b00450","article-title":"Cutting into the Substrate Dominance: pharmacophore and structure-based approaches toward inhibiting human immunodeficiency virus reverse transcriptase-associated ribonuclease H","volume":"53","author":"Wang","year":"2020","journal-title":"Acc. Chem. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114554_bib27","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jo01030a546","article-title":"Nucleosides. V. The Monomesylates of 1-(2'-deoxy-\u03b2-D-lyxofuranosyl)thymine1,2","volume":"29","author":"Horwitz","year":"1964","journal-title":"J. Org. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2022.114554_bib28","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"20","key":"10.1016\/j.ejmech.2022.114554_bib29","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2165\/00002018-199308040-00005","article-title":"Zidovudine toxicity","volume":"8","author":"Rachlis","year":"1993","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2022.114554_bib31","series-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","author":"AIDSinfo","year":"2012"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.antiviral.2006.03.012","article-title":"Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses","volume":"71","author":"Schinazi","year":"2006","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114554_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-199610090-00007","article-title":"Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients","volume":"10","author":"Kuritzkes","year":"1996","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib34","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/infdis\/173.6.1354","article-title":"Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy","volume":"173","author":"Schooley","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"7340","key":"10.1016\/j.ejmech.2022.114554_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/bmj.324.7340.757","article-title":"Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy","volume":"324","author":"Jordan","year":"2002","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nsmb.1908","article-title":"Structural basis of HIV-1 resistance to AZT by excision","volume":"17","author":"Tu","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib37","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/S0968-0896(99)00242-4","article-title":"Abacavir sulfate","volume":"7","author":"Huff","year":"1999","journal-title":"Biorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0006-291X(88)80950-1","article-title":"Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus in vitro","volume":"156","author":"Vince","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib40","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","article-title":"A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity","volume":"41","author":"Daluge","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib41","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/AAC.41.5.1099","article-title":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89","volume":"41","author":"Faletto","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib42","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/AAC.41.5.1094","article-title":"Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89","volume":"41","author":"Tisdale","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114554_bib43","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","article-title":"Abacavir hypersensitivity reaction","volume":"34","author":"Hewitt","year":"2002","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib44","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin. Ther."},{"issue":"17","key":"10.1016\/j.ejmech.2022.114554_bib45","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90253-X","article-title":"Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Lin","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114554_bib46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142 1","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib48","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00002030-200007280-00015","article-title":"A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)","volume":"14","author":"Squires","year":"2000","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib49","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/00002030-200007280-00016","article-title":"A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II)","volume":"14","author":"Eron","year":"2000","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib51","article-title":"Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults","author":"Siegfried","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/381678","article-title":"The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities","volume":"38","author":"Anderson","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114554_bib53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/521150","article-title":"Adverse effects of highly active antiretroviral therapy in developing countries","volume":"45","author":"Subbaraman","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2165\/00003495-199651050-00009","article-title":"Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection","volume":"51","author":"Lea","year":"1996","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.ejmech.2022.114554_bib55","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib56","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1086\/374935","article-title":"Miller Fisher Variant of Guillain-Barr\u00e9 syndrome associated with lactic acidosis and stavudine therapy","volume":"36","author":"Shah","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib57","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.antiviral.2011.08.004","article-title":"In silico study supports the efficacy of a reduced dose regimen for stavudine","volume":"92","author":"Hurwitz","year":"2011","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib59","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2',3'-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6107","key":"10.1016\/j.ejmech.2022.114554_bib60","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/325773a0","article-title":"Strategies for antiviral therapy in AIDS","volume":"325","author":"Mitsuya","year":"1987","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00126334-200212010-00005","article-title":"Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir","volume":"31","author":"Gathe","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-121-4-199408150-00005","article-title":"Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy","volume":"121","author":"Kozal","year":"1994","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00003495-199244010-00008","article-title":"Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection","volume":"44","author":"Faulds","year":"1992","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/jo01339a045","article-title":"Nucleosides. IX. The formation of 2',3'-unsaturated pyrimidine nucleosides via a novel \u03b2-elimination reaction1,2","volume":"31","author":"Horwitz","year":"1966","journal-title":"J. Org. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00002030-199703110-00003","article-title":"The development of resistance of HIV-1 to zalcitabine","volume":"11","author":"Craig","year":"1997","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1128\/AAC.38.2.282","article-title":"Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase","volume":"38","author":"Zhang","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib67","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2165\/00003495-199753060-00009","article-title":"Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection","volume":"53","author":"Adkins","year":"1997","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.ejmech.2022.114554_bib68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199610103351503","volume":"335","author":"Saravolatz","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7326\/0003-4819-116-1-13","article-title":"Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I\/II study","volume":"116","author":"Meng","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/135965359900400105","article-title":"Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells\/mm3","volume":"4","author":"Revicki","year":"1999","journal-title":"Antivir. Ther."},{"issue":"16","key":"10.1016\/j.ejmech.2022.114554_bib71","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine","volume":"334","author":"Collier","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ejmech.2022.114554_bib72","doi-asserted-by":"crossref","first-page":"F61","DOI":"10.1097\/00002030-199612000-00003","article-title":"Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC","volume":"10","author":"Ruiz","year":"1996","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0149-2918(97)80110-5","article-title":"Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus","volume":"19","author":"Lewis","year":"1997","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2022.114554_bib74","series-title":"Therapeutical Application of Phosphonylmethoxy-Alkyl Adenines US4724233A","author":"De Clercq","year":"1985"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib75","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"16","key":"10.1016\/j.ejmech.2022.114554_bib76","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1021\/acs.jmedchem.9b00175","article-title":"Fifty years in search of selective antiviral drugs","volume":"62","author":"De Clercq","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114554_bib77","author":"Gilead Sciences"},{"key":"10.1016\/j.ejmech.2022.114554_bib78","series-title":"Tenofovir Nephrotoxicity: 2011 Update","author":"Fernandez-Fernandez","year":"2011"},{"issue":"9987","key":"10.1016\/j.ejmech.2022.114554_bib79","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114554_bib80","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"key":"10.1016\/j.ejmech.2022.114554_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"issue":"4\u20137","key":"10.1016\/j.ejmech.2022.114554_bib82","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1081\/NCN-100002338","article-title":"Practical synthesis, separation and stereochemical assignment of the PMPA pro-drug GS-7340","volume":"20","author":"Chapman","year":"2001","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0166-3542(92)90026-2","article-title":"Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT","volume":"17","author":"McGuigan","year":"1992","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib84","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib85","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib86","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib87","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib89","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/jac\/dkt532","article-title":"Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults","volume":"69","author":"Markowitz","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib90","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA, Antimicrob","volume":"42","author":"Robbins","year":"1998","journal-title":"Agents Chemother"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib91","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.ejmech.2022.114554_bib92","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib93","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib94","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/aid.2021.0028","article-title":"Tenofovir alafenamide for HIV prevention: review of the proceedings from the Gates foundation long-acting TAF product development meeting","volume":"37","author":"Romano","year":"2021","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052880","article-title":"Caprisa 018: a phase I\/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women","volume":"12","author":"Gengiah","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib96","first-page":"22","article-title":"And tenofovir","volume":"6","author":"Miller","year":"2004","journal-title":"AIDS Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib98","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations","volume":"11","author":"White","year":"2006","journal-title":"Antivir. Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114554_bib100","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","article-title":"Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog","volume":"35","author":"Soudeyns","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114554_bib101","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.36.3.672","article-title":"Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib102","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.36.4.733","article-title":"(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro","volume":"36","author":"Coates","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.36.1.202","article-title":"The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro","volume":"36","author":"Coates","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"25","key":"10.1016\/j.ejmech.2022.114554_bib104","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party, N","volume":"333","author":"Eron","year":"1995","journal-title":"Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib105","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425250903490418","article-title":"Lamivudine for the treatment of HIV","volume":"6","author":"Kumar","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib107","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.37.10.2206","article-title":"Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro","volume":"37","author":"Mathez","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114554_bib108","series-title":"Third Workshop on Viral Resistance","article-title":"Resistance and susceptibility of HIV to the antiviral agents AZT and 3TC: quantitation and evolution in treated patients","author":"Schinazi","year":"1993"},{"key":"10.1016\/j.ejmech.2022.114554_bib109","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"24","key":"10.1016\/j.ejmech.2022.114554_bib110","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1021\/ja00024a058","article-title":"In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs","volume":"113","author":"Choi","year":"1991","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib111","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, Antimicrob","volume":"36","author":"Schinazi","year":"1992","journal-title":"Agents Chemother"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib112","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib113","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.37.4.875","article-title":"Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides","volume":"37","author":"Schinazi","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114554_bib114","series-title":"Frontiers in Viral Hepatitis","first-page":"451","article-title":"Chapter 37 - preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine","author":"Painter","year":"2003"},{"key":"10.1016\/j.ejmech.2022.114554_bib115","first-page":"65","article-title":"Mutations in retroviral genes associated with drug resistance: 2000-2001 update","volume":"8","author":"Schinazi","year":"2000","journal-title":"Int. Antiviral News"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2022.114554_bib116","first-page":"61","article-title":"Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes","volume":"12","author":"Schinazi","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib117","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib118","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1128\/jvi.66.12.7128-7135.1992","article-title":"Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine","volume":"66","author":"Gu","year":"1992","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib119","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/095632020701800505","article-title":"A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine","volume":"18","author":"Borroto-Esoda","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"Anderson","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib121","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2165\/00003495-200565100-00008","article-title":"Emtricitabine: a review of its use in the management of HIV infection","volume":"65","author":"Frampton","year":"2005","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.ejmech.2022.114554_bib122","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","article-title":"Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy","volume":"21","year":"2007","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib123","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.38.12.2743","article-title":"Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis","volume":"38","author":"Martin","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib124","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1586\/14787210.4.6.965","article-title":"Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients","volume":"4","author":"Palacios","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114554_bib126","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2022.114554_bib127","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.2147\/IJN.S215447","article-title":"Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib128","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.46.6.1734-1740.2002","article-title":"Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection","volume":"46","author":"Gish","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114554_bib129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2005-915647","article-title":"Current treatment of chronic hepatitis B: benefits and limitations","volume":"25","author":"Perrillo","year":"2005","journal-title":"Semin. Liver Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib130","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1128\/AAC.48.4.1300-1306.2004","volume":"48","author":"Feng","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2022.114554_bib131","first-page":"98","article-title":"4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl purines and pyrimidines, a new class of anti-herpesvirus agents","volume":"17","author":"Slusarchyk","year":"1992","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114554_bib132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0960-894X(96)00594-X","article-title":"BMS-200475, a novel carbocyclic 2\u2032-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro","volume":"7","author":"Bisacchi","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114554_bib133","series-title":"12th Conference on Retroviruses and Opportunistic Infections","first-page":"22","article-title":"Entecavir in HIV\/HBV co-infected patients: safety and efficacy in a phase II study (ETV-038)","author":"Pessoa","year":"2005"},{"issue":"25","key":"10.1016\/j.ejmech.2022.114554_bib134","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir - effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114554_bib135","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1074\/jbc.M707834200","article-title":"Pre-steady-state kinetic studies establish entecavir-triphosphate as a substrate for HIV-1 reverse transcriptase","volume":"283","author":"Domaoal","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"49","key":"10.1016\/j.ejmech.2022.114554_bib136","doi-asserted-by":"crossref","first-page":"34218","DOI":"10.1074\/jbc.M806797200","article-title":"Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase","volume":"283","author":"Tchesnokov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114554_bib137","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","year":"2022"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib138","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114554_bib139","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2022.114554_bib140","article-title":"Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B","volume":"8","author":"Roade","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib141","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jvh.12732","article-title":"Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment","volume":"24","author":"Lok","year":"2017","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib142","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP3087","article-title":"Factors associated with HBV virological breakthrough","volume":"22","author":"Sheppard-Law","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2022.114554_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.104958","article-title":"Exploration of long-acting implant formulations of hepatitis B drug entecavir","volume":"136","author":"Henry","year":"2019","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2022.114554_bib144","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2019.01.052","article-title":"Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: preparation and in vitro and in vivo evaluation","volume":"560","author":"Zhang","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2022.114554_bib145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2015.05.049","article-title":"An injectable liquid crystal system for sustained delivery of entecavir","volume":"490","author":"Lim","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114554_bib146","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","article-title":"2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants","volume":"40","author":"Kawamoto","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"35","key":"10.1016\/j.ejmech.2022.114554_bib147","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"51","key":"10.1016\/j.ejmech.2022.114554_bib148","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"33","key":"10.1016\/j.ejmech.2022.114554_bib149","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib150","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1128\/AAC.01703-13","article-title":"Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine","volume":"57","author":"Kirby","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114554_bib151","first-page":"40","article-title":"The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase","volume":"57","author":"Kirby","year":"2011","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114554_bib152","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1742-4690-10-65","article-title":"Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA","volume":"10","author":"Michailidis","year":"2013","journal-title":"Retrovirology"},{"issue":"9","key":"10.1016\/j.ejmech.2022.114554_bib153","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1128\/AAC.00283-13","article-title":"Evaluation of combinations of 4'-ethynyl-2-fluoro-2'-deoxyadenosine with clinically used antiretroviral drugs","volume":"57","author":"Hachiya","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114554_bib154","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01167-21","article-title":"Development of human immunodeficiency virus type 1 resistance to 4'-ethynyl-2-fluoro-2'-deoxyadenosine starting with wild-type or nucleoside reverse transcriptase inhibitor-resistant strains","volume":"65","author":"Cilento","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114554_bib155","series-title":"Islatravir","author":"Drug Database","year":"2021"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114554_bib156","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","article-title":"Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial","volume":"27","author":"Matthews","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114554_bib157","series-title":"Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection","year":"2021"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114554_bib158","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/v2040880","article-title":"HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate","volume":"2","author":"Maga","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2022.114554_bib159","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bcp.2017.04.001","article-title":"Guanine \u03b1-carboxy nucleoside phosphonate (G-\u03b1-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses","volume":"136","author":"Balzarini","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"13","key":"10.1016\/j.ejmech.2022.114554_bib160","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1016\/j.bmcl.2013.04.043","article-title":"Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors, Bioorg","volume":"23","author":"Sturino","year":"2013","journal-title":"Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114554_bib161","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1128\/AAC.00113-13","article-title":"Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series","volume":"57","author":"Rajotte","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114554_bib162","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.bmcl.2013.02.021","article-title":"Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors, Bioorg","volume":"23","author":"James","year":"2013","journal-title":"Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114554_bib163","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.bmcl.2013.02.042","article-title":"Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors","volume":"23","author":"Tremblay","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114554_bib164","series-title":"Innovative Drug Synthesis","first-page":"61","article-title":"Sofosbuvir (sovaldi): the first-in-class HCV NS5B nucleotide polymerase inhibitor","author":"Schinazi","year":"2015"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:40:56Z","timestamp":1759329656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":164,"alternative-id":["S0223523422004561"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114554","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV nucleoside reverse transcriptase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114554"}}